文献速递脑血管病

低剂量利伐沙班与房颤患者不良事件风险

Low-Dose Rivaroxaban and Risks of Adverse Events in Patients With Atrial Fibrillation.
PubMed 文献 · Stroke · 2019-07-10

本研究在台湾一家三级医疗中心纳入2214例接受利伐沙班治疗的房颤患者,比较标签内剂量与超说明书低剂量(10 mg/d)的缺血性卒中及颅内出血风险。结果显示,超说明书低剂量利伐沙班与缺血性卒中风险增加相关(校正HR 2.75,95%CI 1.62-4.69,P<0.001),而颅内出血风险无显著差异,且标签内剂量具有正向净临床获益。

要点

  • 超说明书低剂量利伐沙班增加房颤患者缺血性卒中风险。
  • 低剂量与标签内剂量的颅内出血风险无显著差异。
  • 标签内剂量利伐沙班具有正向净临床获益。

核心结论

  • 对于亚洲房颤患者,应避免超说明书低剂量利伐沙班,因其增加缺血性卒中风险且不降低颅内出血风险。

研究设计与样本

  • 回顾性队列研究,纳入台湾一家三级医疗中心2214例年龄≥20岁接受利伐沙班治疗的房颤患者。
  • 患者分为标签内剂量组(n=1630,符合ROCKET-AF或J-ROCKET剂量标准)和超说明书低剂量组(n=584,估算肾小球滤过率>50 mL/min者10 mg/d)。

主要发现

  • 与标签内剂量组相比,超说明书低剂量组缺血性卒中风险增加(校正HR 2.75;95%CI 1.62-4.69;P<0.001)。
  • 两组颅内出血风险无显著差异(校正HR 0.62;95%CI 0.32-1.20;P=0.213)。
  • 标签内剂量利伐沙班在不同加权模型中均与正向净临床获益相关。
  • 倾向性匹配队列中结果一致。

临床怎么用

  • 临床应按照ROCKET-AF或J-ROCKET标准给予利伐沙班标签内剂量,避免超说明书低剂量。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background and Purpose- In the daily practice, low-dose nonvitamin K antagonist oral anticoagulants are commonly used among Asian patients with atrial fibrillation (AF). The aim of the present study was to compare the risks of ischemic stroke, intracranial hemorrhage, and net clinical benefit of Asian patients with AF treated with off-label low-dose and on-label dosing rivaroxaban. Methods- A total of 2214 patients with AF aged ≥20 years treated with rivaroxaban at a tertiary medical center in Taiwan were studied. Patients were categorized into 2 groups: (1) on-label dose (n=1630): ROCKET-AF or J-ROCKET dosage criteria; and (2) off-label low-dose (10 mg/d for patients with an estimated glomerulus filtration rate >50 mL/min, n=584). The risks of ischemic stroke and intracranial hemorrhage were compared between 2 groups. Results- Compared with the on-label dose group, off-label low-dose rivaroxaban was associated with an increased risk of ischemic stroke with an adjusted hazard ratio of 2.75; 95% CI =1.62-4.69; P<0.001). The risk intracranial hemorrhage did not differ significantly between the on-label and off-label low-dosing groups (adjusted hazard ratio =0.62; 95% CI =0.32-1.20; P=0.213). Compared with off-label low-dose group, on-label dosing rivaroxaban was associated with a positive net clinical benefit in different weighted models. The results were consistent among the propensity-matched cohort. Conclusions- Off-label low-dosing rivaroxaban should be avoided for Asian patients with AF giving the higher risk of ischemic stroke without risk reduction in intracranial hemorrhage compared with on-label dosing.

来源:Stroke,查看原文。版权归原作者所有。

引用

  1. Cheng WH, Chao TF, Lin YJ, et al. Low-Dose Rivaroxaban and Risks of Adverse Events in Patients With Atrial Fibrillation. Stroke. 2019. PMID: 31288672. doi:10.1161/STROKEAHA.119.025623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。